<p>Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.</p>

Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Sign up to save your podcasts

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

More shows like GRACEcast Radiation Oncology Audio

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Video

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Cancer 101 Audio

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video